NEUP Stock Summary and Trading Ideas (Neuphoria Therapeutics | NASDAQ:NEUP)

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.

Neuphoria Therapeutics trades on the NASDAQ stock market under the symbol NEUP.

As of October 1, 2026, NEUP stock price declined to $3.51 with 14,276 million shares trading.

NEUP has a beta of -0.14, meaning it tends to be less sensitive to market movements. NEUP has a correlation of 0.00 to the broad based SPY ETF.

NEUP has a market cap of $18.99 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that NEUP belongs to (by Net Assets): PSIL, VTI, VXF.

NEUP has underperformed the market in the last year with a price return of -70.2% while the SPY ETF gained +15.8%. NEUP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.7% and -6.1%, respectively, while the SPY returned +2.6% and +1.6%, respectively.

NEUP support price is $3.48 and resistance is $3.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEUP shares will trade within this expected range on the day.